trimethylglycine-liver-enzymes

この研究の注釈：

10g of betaine twice daily over the course of one year in persons with nonalcoholic fatty liver appeared to significantly reduce ALT (), AST (), and ALP () liver enzyme values relative to baseline (no placebo control) with five subjects finding normalization of liver fat.

In an intent to treat analysis, over 90% of subjects reported reductions in liver fat or inflammation in general; 36.4% of subjects who reported benefit to fibrosis scores (11 out of 23) had more than two stages of improvement, and only one subject had a worsening of fibrosis.

この研究の注釈：

Supplementation of 10g betaine twice daily for one year in persons with nonalcoholic fatty liver disease was able to increase methionine and SAMe levels, but did not reduce S-adenosylhomocysteine levels. Alongside this, there were failures to reduce liver enzymes or fibrotic scores, although liver fat (steatosis) was reduced with betaine and the progression of the disease state was lower in betaine relative to placebo.

General symptoms and well being was not different between groups.

この研究の注釈：

In otherwise healthy adults given betaine supplementation at 4g daily for a period of six months, there was no significant influence on organ function biomarkers (kidney and liver) nor any significant influence on lipid profiles. Homocysteine was actually not significantly affected, as the 12% difference between groups (increase in placebo, stasis in supplementation) faile to reach statistical significance.

An increase was noted in apolipoprotein A1 and PAI-1.

この研究の注釈：

In obese subjects given supplementation of betaine at 6g daily for 12 weeks was able to decrease homocysteine (9%) relative to placebo but the decrease in total cholesterol and LDL seen in placebo was not present in betaine intervention; there was no influence on body weight. There was no influence on plasma nor RBC folate concentrations.

The increase in ALP (liver enzyme) seen in placebo was prevented with betaine.

この研究の注釈：

Supplementation of betaine at 500mg twice daily over the course of one year was able to fully normalize liver enzymes in three out of seven patients and reduce them by more than 50% in three others, with one nonresponder and the dropouts (before the year the trial lasted) also noting a 38-39% reduction.